Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age

A cross-sectional study

Osamu Toyoshima, Toshihiro Nishizawa, Kosuke Sakitani, Tadahiro Yamakawa, Yoshiyuki Takahashi, Nobutake Yamamichi, Keisuke Hata, Yasuyuki Seto, Kazuhiko Koike, Hidenobu Watanabe, Hidekazu Suzuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AIM: To clarify the role of serum anti-Helicobacter pylori (H. pylori) antibody titers in gastric cancer. METHODS: In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/mL were classified into groups A, B, C, and D, respectively. RESULTS In total, 874 participants were analyzed with 70%, 16%, 8.7%, and 5.1% of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity (P = 0.0094), atrophy (P = 0.0076), and age 40-59 years (vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D. CONCLUSION: Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer.

Original languageEnglish
Pages (from-to)4061-4068
Number of pages8
JournalWorld Journal of Gastroenterology
Volume24
Issue number35
DOIs
Publication statusPublished - 2018 Sep 21

Fingerprint

Helicobacter pylori
Atrophy
Stomach
Cross-Sectional Studies
Antibodies
Serum
Metaplasia
Stomach Neoplasms
Digestive System Endoscopy
Venules
Helicobacter Infections
Gastritis
Duodenal Ulcer
Gastroesophageal Reflux
Polyps
Multivariate Analysis
Inflammation

Keywords

  • Antibody
  • Endoscopy
  • Gastric cancer
  • Gastritis
  • Helicobacter pylori

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age : A cross-sectional study. / Toyoshima, Osamu; Nishizawa, Toshihiro; Sakitani, Kosuke; Yamakawa, Tadahiro; Takahashi, Yoshiyuki; Yamamichi, Nobutake; Hata, Keisuke; Seto, Yasuyuki; Koike, Kazuhiko; Watanabe, Hidenobu; Suzuki, Hidekazu.

In: World Journal of Gastroenterology, Vol. 24, No. 35, 21.09.2018, p. 4061-4068.

Research output: Contribution to journalArticle

Toyoshima, O, Nishizawa, T, Sakitani, K, Yamakawa, T, Takahashi, Y, Yamamichi, N, Hata, K, Seto, Y, Koike, K, Watanabe, H & Suzuki, H 2018, 'Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study', World Journal of Gastroenterology, vol. 24, no. 35, pp. 4061-4068. https://doi.org/10.3748/wjg.v24.i35.4061
Toyoshima, Osamu ; Nishizawa, Toshihiro ; Sakitani, Kosuke ; Yamakawa, Tadahiro ; Takahashi, Yoshiyuki ; Yamamichi, Nobutake ; Hata, Keisuke ; Seto, Yasuyuki ; Koike, Kazuhiko ; Watanabe, Hidenobu ; Suzuki, Hidekazu. / Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age : A cross-sectional study. In: World Journal of Gastroenterology. 2018 ; Vol. 24, No. 35. pp. 4061-4068.
@article{b8c0fb084cfe4e39ae9b1f04234f91af,
title = "Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study",
abstract = "AIM: To clarify the role of serum anti-Helicobacter pylori (H. pylori) antibody titers in gastric cancer. METHODS: In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/mL were classified into groups A, B, C, and D, respectively. RESULTS In total, 874 participants were analyzed with 70{\%}, 16{\%}, 8.7{\%}, and 5.1{\%} of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity (P = 0.0094), atrophy (P = 0.0076), and age 40-59 years (vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D. CONCLUSION: Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer.",
keywords = "Antibody, Endoscopy, Gastric cancer, Gastritis, Helicobacter pylori",
author = "Osamu Toyoshima and Toshihiro Nishizawa and Kosuke Sakitani and Tadahiro Yamakawa and Yoshiyuki Takahashi and Nobutake Yamamichi and Keisuke Hata and Yasuyuki Seto and Kazuhiko Koike and Hidenobu Watanabe and Hidekazu Suzuki",
year = "2018",
month = "9",
day = "21",
doi = "10.3748/wjg.v24.i35.4061",
language = "English",
volume = "24",
pages = "4061--4068",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "35",

}

TY - JOUR

T1 - Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age

T2 - A cross-sectional study

AU - Toyoshima, Osamu

AU - Nishizawa, Toshihiro

AU - Sakitani, Kosuke

AU - Yamakawa, Tadahiro

AU - Takahashi, Yoshiyuki

AU - Yamamichi, Nobutake

AU - Hata, Keisuke

AU - Seto, Yasuyuki

AU - Koike, Kazuhiko

AU - Watanabe, Hidenobu

AU - Suzuki, Hidekazu

PY - 2018/9/21

Y1 - 2018/9/21

N2 - AIM: To clarify the role of serum anti-Helicobacter pylori (H. pylori) antibody titers in gastric cancer. METHODS: In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/mL were classified into groups A, B, C, and D, respectively. RESULTS In total, 874 participants were analyzed with 70%, 16%, 8.7%, and 5.1% of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity (P = 0.0094), atrophy (P = 0.0076), and age 40-59 years (vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D. CONCLUSION: Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer.

AB - AIM: To clarify the role of serum anti-Helicobacter pylori (H. pylori) antibody titers in gastric cancer. METHODS: In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/mL were classified into groups A, B, C, and D, respectively. RESULTS In total, 874 participants were analyzed with 70%, 16%, 8.7%, and 5.1% of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity (P = 0.0094), atrophy (P = 0.0076), and age 40-59 years (vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D. CONCLUSION: Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer.

KW - Antibody

KW - Endoscopy

KW - Gastric cancer

KW - Gastritis

KW - Helicobacter pylori

UR - http://www.scopus.com/inward/record.url?scp=85053669865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053669865&partnerID=8YFLogxK

U2 - 10.3748/wjg.v24.i35.4061

DO - 10.3748/wjg.v24.i35.4061

M3 - Article

VL - 24

SP - 4061

EP - 4068

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 35

ER -